{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:54:50Z","timestamp":1782888890394,"version":"3.54.5"},"reference-count":67,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Recently developed effective CFTR modulator drugs have substantially altered the disease trajectory of people with CF (pwCF) with access to these new therapies. Yet globally, this transformation to causal treatment remains profoundly unequal, with a substantial proportion of pathogenic CFTR variants in populations of non-European ancestry neither detectable by widely used genetic CF screening panels nor approved for or responsive to modulator therapies. This narrative review organizes the current global treatment realities along three axes: pwCF with access to CFTR modulator therapy; pwCF experiencing structural barriers in proper diagnosis and drug access; and those pwCF with biological realities not predisposing to currently approved effective CF drugs.<\/jats:p>","DOI":"10.3390\/children13070878","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:06:34Z","timestamp":1782875194000},"page":"878","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving Cystic Fibrosis Therapy: The Good, the Sad, and the Hopeful"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7232-7828","authenticated-orcid":false,"given":"Dominik","family":"Funken","sequence":"first","affiliation":[{"name":"Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada"},{"name":"Program in Translational Medicine, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-9642","authenticated-orcid":false,"given":"Hartmut","family":"Grasemann","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada"},{"name":"Program in Translational Medicine, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada"},{"name":"Institute of Medical Science Temerty, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13073-024-01316-5","article-title":"Diversity of CFTR variants across ancestries characterized using 454,727 UK biobank whole exome sequences","volume":"16","author":"Ideozu","year":"2024","journal-title":"Genome Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1002\/ppul.26621","article-title":"Cystic fibrosis screen-positive neonates with one pathogenic variant still warrant sweat testing","volume":"58","author":"Rock","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic Fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_4","unstructured":"Goldman, L., and Cooney, K.A. (2024). Cystic fibrosis. Goldman-Cecil Medicine, Elsevier. [27th ed.]."},{"key":"ref_5","first-page":"599","article-title":"Analysis of the Genome Aggregation Database (gnomAD) reveals a global burden of cystic fibrosis and the need for improved diagnosis and care","volume":"29","author":"Bar","year":"2026","journal-title":"eBioMedicine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): Results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/ppul.26954","article-title":"International disparities in diagnosis and treatment access for cystic fibrosis","volume":"59","author":"Guo","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"ref_11","unstructured":"Canada\u2019s Drug Agency (CDA-AMC) (2026, April 15). Pharmacoeconomic Review: Elexacaftor\/Tezacaftor\/Ivacaftor (Trikafta), Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK603347\/."},{"key":"ref_12","unstructured":"Canada\u2019s Drug Agency (CDA-AMC) (2026, April 15). Reimbursement Review: Elexacaftor\/Tezacaftor\/Ivacaftor (Trikafta). Available online: https:\/\/www.cda-amc.ca\/elexacaftortezacaftorivacaftor-and-ivacaftor-1."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: Real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_14","first-page":"599","article-title":"Real-world outcomes and direct care cost before and after elexacaftor\/tezacaftor\/ivacaftor initiation in commercially insured members with cystic fibrosis","volume":"29","author":"Marshall","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"108410","DOI":"10.1016\/j.rmed.2025.108410","article-title":"Real-world outcomes after initiation of Elexacaftor\/tezacaftor\/ivacaftor in an adolescent cohort with cystic fibrosis","volume":"249","author":"Johnston","year":"2025","journal-title":"Respir. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_17","unstructured":"(2026, May 10). Alyftrek|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alyftrek."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(24)00407-7","article-title":"Vanzacaftor-tezacaftor-deutivacaftor for children aged 6\u201311 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): An analysis from a single-arm, phase 3 trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_19","unstructured":"Vertex Pharmaceuticals (2026, April 15). Vertex Announces US FDA Approval for Label Extensions of ALYFTREK and TRIKAFTA, Expanding Availability of These Medicines to Approximately 95 Percent of All People with CF in the United States. Available online: https:\/\/news.vrtx.com\/news-releases\/news-release-details\/vertex-announces-us-fda-approval-label-extensions-alyftrekr-and."},{"key":"ref_20","unstructured":"Zolin, A., Adamoli, A., and Bakkeheim, E. (2026, April 15). ECFSPR Annual Report 2023. Available online: https:\/\/www.ecfs.eu\/ecfspr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chest.2022.07.004","article-title":"The Changing Epidemiology of Cystic Fibrosis: The Implications for Adult Care","volume":"163","author":"Burgel","year":"2023","journal-title":"Chest"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Scotet, V., L\u2019hostis, C., and F\u00e9rec, C. (2020). The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes, 11.","DOI":"10.3390\/genes11060589"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1700763","DOI":"10.1183\/13993003.00763-2017","article-title":"Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: Update and sensitivity analysis","volume":"50","author":"Burgel","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_24","unstructured":"Cystic Fibrosis Foundation (2025). 2024 Patient Registry Highlights Report, Cystic Fibrosis Foundation. Available online: https:\/\/www.cff.org\/sites\/default\/files\/2025-05\/2024-Patient-Registry-Highlights-Report.pdf."},{"key":"ref_25","unstructured":"N\u00e4hrlich, L., Burkhart, M., and Jaumann, B. (2026, April 15). Deutsches Mukoviszidose-Register, Berichtsband 2024. Bonn. Available online: https:\/\/www.muko.info\/fileadmin\/user_upload\/was_wir_tun\/register\/berichtsbaende\/berichtsband_2024.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcf.2022.04.007","article-title":"Current prices versus minimum costs of production for CFTR modulators","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_27","first-page":"37","article-title":"Cystic fibrosis in low and middle-income countries (LMIC): A view from four different regions of the world","volume":"38","author":"Zampoli","year":"2021","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jcf.2023.09.008","article-title":"Standards for the care of people with cystic fibrosis (CF): A timely and accurate diagnosis","volume":"22","author":"Castellani","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"McGarry, M.E., Raraigh, K.S., Farrell, P., Shropshire, F., Padding, K., White, C., Dorley, M.C., Hicks, S., Ren, C.L., and Tullis, K. (2025). Cystic Fibrosis Newborn Screening: A Systematic Review-Driven Consensus Guideline from the United States Cystic Fibrosis Foundation. Int. J. Neonatal Screen., 11.","DOI":"10.3390\/ijns11020024"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ppul.26209","article-title":"Detection of disease-causing CFTR variants in state newborn screening programs","volume":"58","author":"McGarry","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s13023-024-03506-1","article-title":"Diagnosing cystic fibrosis in low- and middle-income countries: Challenges and strategies","volume":"19","author":"Fuhrer","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e71445","DOI":"10.1002\/ppul.71445","article-title":"Expanding Cystic Fibrosis Registries to the Rest of the World","volume":"61","author":"Naehrlich","year":"2026","journal-title":"Pediatr. Pulmonol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zampoli, M., Morrow, B.M., and Paul, G. (2023). Real-world disparities and ethical considerations with access to CFTR modulator drugs: Mind the gap!. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1163391"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.jcf.2022.03.006","article-title":"Global access to affordable CFTR modulator drugs: Time for action!","volume":"21","author":"Zampoli","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jcf.2025.02.010","article-title":"Strategies used to access CFTR modulators in countries without reimbursement agreements","volume":"24","author":"Guo","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1513\/AnnalsATS.202402-201OC","article-title":"Long-Term Impact of Lumacaftor\/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2\u20135 Years of Age Homozygous for F508del-CFTR: A Phase 2, Open-Label Clinical Trial","volume":"21","author":"Stahl","year":"2024","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1513\/AnnalsATS.202410-1070LE","article-title":"Is There a Role Lumacaftor\/Ivacaftor Young Children with Cystic Fibrosis?","volume":"22","author":"Martin","year":"2025","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMe1712335","article-title":"CFTR Modulator Therapy for Cystic Fibrosis","volume":"377","author":"Grasemann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/cpt.3214","article-title":"Pharmacokinetic Enhancement of Elexacaftor\/Tezacaftor\/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access","volume":"115","author":"Hong","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jcf.2023.09.003","article-title":"Global disparities in cystic fibrosis outcomes prior to CFTR modulators: A CF registries cohort study in South Africa and Canada","volume":"23","author":"Zampoli","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_41","first-page":"707","article-title":"Cystic Fibrosis Care in South Africa: Facing the Challenge of Diversity and Inequality","volume":"23","author":"Zampoli","year":"2025","journal-title":"Pediatr. Pulmonol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jcf.2024.04.018","article-title":"The clinical utility of sequencing the entirety of CFTR","volume":"23","author":"Sheridan","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kondratyeva, E., Efremova, A., Melyanovskaya, Y., Krasnova, M., Milovanov, M., and Shchagina, O. (2025). L467F;F508del Complex Allele in a Heterozygous State with CFTRdele2,3: What to Expect from CFTR Modulators?. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262311742"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Krasnova, M., Efremova, A., Bukhonin, A., Zhekaite, E., Bukharova, T., Melyanovskaya, Y., Goldshtein, D., and Kondratyeva, E. (2023). The Effect of Complex Alleles of the CFTR Gene on the Clinical Manifestations of Cystic Fibrosis and the Effectiveness of Targeted Therapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010114"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"17534666251323194","DOI":"10.1177\/17534666251323194","article-title":"Cystic fibrosis: New challenges and perspectives beyond elexacaftor\/tezacaftor\/ivacaftor","volume":"19","author":"Terlizzi","year":"2025","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jcf.2021.01.007","article-title":"Challenges in the use of highly effective modulator treatment for cystic fibrosis","volume":"20","author":"Ramos","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2501594","DOI":"10.1183\/13993003.01594-2025","article-title":"Impact of CFTR Modulator Concentrations on Clinical Response in Cystic Fibrosis","volume":"67","author":"Chalamalla","year":"2026","journal-title":"Eur. Respir. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2600247","DOI":"10.1183\/13993003.00247-2026","article-title":"Precision medicine in the era of CFTR modulator therapy: What comes next?","volume":"67","author":"Grasemann","year":"2026","journal-title":"Eur. Respir. J."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Piehler, L., Thalemann, R., Lehmann, C., Thee, S., R\u00f6hmel, J., Syunyaeva, Z., Stahl, M., Mall, M.A., and Graeber, S.Y. (2023). Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on mental health of patients with cystic fibrosis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1179208"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Dagenais, R.V.E., Su, V.C., and Quon, B.S. (2021). Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10010023"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ibrahim, H., Danish, H., Morrissey, D., Deasy, K.F., McCarthy, M., Dorgan, J., Fleming, C., Howlett, C., Twohig, S., and Vagg, T. (2023). Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1156621"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"106878","DOI":"10.1016\/j.rmed.2022.106878","article-title":"Who are the 10%?\u2014Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies","volume":"199","author":"Desai","year":"2022","journal-title":"Respir. Med."},{"key":"ref_53","first-page":"49","article-title":"Patients not eligible for CFTR-modulators (CFTRm) in Europe: Characteristics and distribution","volume":"9","author":"Tomarelli","year":"2023","journal-title":"ERJ Open Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jcf.2024.02.006","article-title":"In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis","volume":"23","author":"Bihler","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1164\/rccm.202402-0389CI","article-title":"Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial","volume":"210","author":"Davies","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jcf.2023.04.008","article-title":"Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1\/2 clinical study","volume":"22","author":"Rowe","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.stem.2019.11.002","article-title":"High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia","volume":"26","author":"Vaidyanathan","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_58","first-page":"278","article-title":"Overcoming the Undesirable CRISPR-Cas9 Expression in Gene Correction","volume":"24","author":"Xia","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1038\/s41467-021-24575-x","article-title":"A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion","volume":"12","author":"Sharma","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_60","unstructured":"Cystic Fibrosis Foundation (2026, May 01). Drug Development Pipeline. Available online: https:\/\/apps.cff.org\/trials\/pipeline\/."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.apsb.2025.11.028","article-title":"Applications of AI\/ML in accelerating the development of pulmonary drug delivery system","volume":"16","author":"Jiang","year":"2026","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.diii.2025.10.009","article-title":"From voxel to treatment response: Rethinking the role of imaging in cystic fibrosis in the era of artificial intelligence","volume":"107","author":"Pozzessere","year":"2026","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jcf.2025.01.006","article-title":"Racial disparities in lung transplantation for cystic fibrosis in the era of highly effective modulator therapy","volume":"24","author":"Ruck","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1513\/AnnalsATS.202001-030OC","article-title":"Impact of Socioeconomic Position on Access to the U.S. Lung Transplant Waiting List in a Matched Cystic Fibrosis Cohort","volume":"17","author":"Lehr","year":"2020","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2500150","DOI":"10.1183\/13993003.00150-2025","article-title":"Reduction of systemic inflammation by elexacaftor\/tezacaftor\/ivacaftor correlates with lung function improvement in cystic fibrosis","volume":"66","author":"Halle","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1513\/AnnalsATS.202507-817OC","article-title":"Long-term Reductions in Inflammation in People with Cystic Fibrosis Treated with Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"23","author":"Sagel","year":"2025","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_67","first-page":"2600247","article-title":"Beyond F508del: Equity as the next frontier in cystic fibrosis","volume":"67","author":"Cohen","year":"2026","journal-title":"Lancet Reg. Health Am."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/7\/878\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:18:55Z","timestamp":1782883135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/7\/878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":67,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["children13070878"],"URL":"https:\/\/doi.org\/10.3390\/children13070878","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}